Perioperative Blood Loss in South African Primary Hip Arthroplasty Patients by Khattab, Mohamed S. & Moodley, Yoshan





Perioperative blood loss in South African primary hip 
arthroplasty patients
Abstract
Background: Perioperative blood loss in South 
African (SA) primary hip arthroplasty patients has 
not been described. This information could improve 
patient management during the perioperative period in 
this setting. Our study objectives were to 1) determine 
perioperative blood loss in SA primary hip arthroplasty 
patients, and 2) determine which characteristics are 
associated with major perioperative blood loss in SA 
primary hip arthroplasty patients.
Methods: This was a retrospective cohort study of  
174 patients who underwent primary hip arthroplasty 
over a 22-month period at the Inkosi Albert Luthuli 
Hospital, SA. All patients were part of  a pre-existing 
registry.  Data for each patient included: Age, gender, 
anthropometric measurements, comorbidity, orthopaedic 
variables, laboratory test results, American Society of  
Anesthesiologists Score, general anaesthesia, duration 
of  surgery, preoperative tranexamic acid, postoperative 
thromboprophylaxis, and perioperative blood transfusion. 
Estimated perioperative blood loss (in mL) was calculated 
using the Gross Equation.  Minimum, maximum, mean, 
and median perioperative blood loss were calculated. 
Major perioperative blood loss was defined as an estimated 
perioperative blood loss which was >75th percentile 
obtained for the study sample.  Data were analyzed using 
appropriate methods.   
Results: Perioperative blood loss ranged from 10.3 
mL to 3041.8 mL. Mean perioperative blood loss was 
1103.1 ± 556.2 mL.  Median perioperative blood loss was 
1008.8 mL, with an interquartile range of  706.2–1357.0 
mL. Independent statistical associations were observed 
between major perioperative blood loss and the following 
characteristics: chronic obstructive pulmonary disease 
(OR: 3.01, 95% CI: 1.01–8.95; p=0.048), preoperative 
tranexamic acid (OR: 0.28, 95% CI: 0.13–0.63; p=0.002), 
and perioperative blood transfusion (OR: 10.18, 95% CI: 
3.53–29.34; p<0.001).
Conclusion: The levels of  perioperative blood loss 
observed in our sample of  SA primary hip arthroplasty 
patients are consistent with the range of  estimated 
blood loss reported in the published literature for hip 
arthroplasty populations in other countries.  SA primary 
hip arthroplasty patients who suffer major perioperative 
blood loss are more likely to have COPD or require 
perioperative blood transfusion.  Preoperative tranexamic 
acid was protective against major perioperative blood loss. 
Introduction
Primary hip arthroplasty has become a commonly per-formed surgery due to its success in the management of  orthopaedic hip disorders. It is an extensive surgical 
procedure, and blood loss during the perioperative period is 
inevitable.1,2  The usual perioperative blood loss for patients 
undergoing primary hip arthroplasty varies according to set-
ting.  Blood loss following primary hip arthroplasty in Chinese 
settings ranges between 1155mL and 1785mL,3,4 while periop-
erative blood loss in a British setting was estimated at almost 
1500mL.5  Newman and colleagues reported total blood loss 
in an American setting to be 1386mL.6  In another American 
study, Grosflam and colleagues reported a range of  blood loss 
following hip arthroplasty of  between 1.4 and 5.8 units of  red 
cells (420-1740mL).7 In a Nigerian setting, blood loss following 
primary hip arthroplasty was estimated at 1786mL.8  Excessive 
blood loss is associated with a higher risk of  fatal and nonfatal 
perioperative complications, and might also result in the need 
for blood transfusion. There are several patient, anaesthetic, 
and procedural characteristics associated with increased peri-
operative bleeding following primary hip arthroplasty in non-
South African (SA) settings.2  These include: older age, female 
sex, obesity, rheumatoid arthritis, hypertension, high American 
Society of  Anesthesiologists (ASA) Score, long duration of  op-
eration, general anaesthesia, not using tranexamic acid, and 
not using postoperative thromboprophylaxis.2  
However, levels of  perioperative blood loss in SA patients 
undergoing primary hip arthroplasty has not been described. 
While there is uncertainty with regard to the expected blood loss 
following primary hip arthroplasty in a South African setting, we 
hypothesize that this would lie within the range reported for the 
various countries above (between 420mL and 1786mL).  Con-
sidering the aforementioned association of  excessive periopera-
tive blood loss with perioperative outcomes and blood product 
utilization, efforts in understanding perioperative blood loss 
would be beneficial in improving patient management during 
the perioperative period in this setting. This is even more impor-
tant when one considers that if  the perioperative blood loss for 
primary hip arthroplasty in our SA setting lies within the range 
reported for other non-SA settings, then it could possibly result 
Mohamed S. Khattab (MD)1,a; Yoshan Moodley (PhD)2,b
1Department of Anesthetics, University of KwaZulu-Natal, Private Bag X7, Congella 4013, South Africa
2Faculty of Health and Environmental Sciences, Central University of Technology, Bloemfontein, South Africa
aMaster’s student, bResearch associate
30
Perioperative blood loss in South African primary hip arthroplasty patients
UTMJ • Volume 96, Number 3, June 2019
 Primary Research
in transfusions between 2 and 6 units of  red cells in order to 
restore preoperative blood volumes. Blood products are a scarce 
resource in SA,9 and elective procedures are often cancelled or 
deferred as a result of  low blood product stocks. The burden of  
certain bleeding risk factors could also be different between sur-
gical populations from different settings, therefore necessitating 
the identification of  setting-specific characteristics associated 
with major perioperative blood loss.  Therefore, the objectives 
of  this study were to 1)  determine perioperative blood loss in 
SA primary hip arthroplasty patients, and 2) determine which 
characteristics (patient, anaesthetic, and procedural character-
istics) are associated with major perioperative blood loss in SA 
primary hip arthroplasty patients. 
 
Methods
This was a retrospective cohort study involving adult pa-
tients who were admitted for primary hip arthroplasty at the 
Inkosi Albert Luthuli Central Hospital (IALCH) in KwaZulu-
Natal, SA, between 23 September 2014 and 28 July 2016.  All 
patients were part of  a pre-existing registry.  These patients 
were identified from theatre lists during the specified study pe-
riod.  Specific inclusion and exclusion criteria (Table 1) were 
used when identifying eligible patients for the study sample.
Table 1. Inclusion and exclusion criteria used in this study
Inclusion criteria Exclusion criteria
Patients aged 18 years or older Patients previously included in this study 
(i.e. patients were included only once in 
the analysis)
Patients who underwent primary hip 
arthroplasty at IALCH between 23 Sep-
tember 2014 and 28 July 2016 
Patients with height and weight missing 
in their medical records (required for 
calculation of blood loss)
Data
During the chart review process for the pre-existing reg-
istry, various patient, clinical, and procedural characteristics 
were collected for each eligible patient in a Microsoft Excel® 
spreadsheet. This included patient age and gender, anthropo-
metric measurements, comorbidity, orthopaedic condition and 
other orthopaedic variables, laboratory test results (including 
pre- and postoperative haematocrit), American Society of  An-
aesthesiologists Score, general anaesthesia, duration of  surgery, 
preoperative tranexamic acid use, postoperative thrombopro-
phylaxis use, and perioperative blood transfusion. In addition, 
use of  medications such as aspirin and nonsteroidal anti-inflam-
matory drugs was also recorded. Estimated perioperative blood 
loss (in mL) for each patient was calculated using the Gross 
Equation.10,11  The equation uses the estimated blood volume 
of  the patient, as well as preoperative, lowest postoperative, and 
average haematocrit measurements to calculate estimated peri-
operative blood loss.10,11 Major perioperative blood loss was de-
fined as an estimated perioperative blood loss which was >75th 
percentile obtained for the study sample. We chose to use the 
75th percentile of  blood loss in mL (as estimated by the Gross 
Equation) as the threshold for major perioperative blood loss 
in this study, as values which lie above the 75th percentile for a 
continuous variable are considered to be in the highest statisti-
cal quartile for that variable.12 We also believe that determin-
ing a setting-specific threshold for major perioperative blood 
loss was appropriate as there is great variation in perioperative 
blood loss reported between settings.3-8  
Statistical Analysis
The minimum, maximum, mean with standard deviation, 
and median with interquartile range (IQR) perioperative blood 
loss were calculated using conventional methods.13 Potential 
associations between various characteristics and major periop-
erative blood loss were investigated initially investigated using 
univariate statistical methods (χ2 test, or Fisher’s exact test for 
categorical variables and the Mann-Whitney test for continu-
ous variables). This was done in order to determine the distri-
bution of  major perioperative blood loss between the different 
categories of  characteristics, and also to select the most appro-
priate characteristics for inclusion in the multivariate statistical 
analysis. Characteristics with p<0.100 in the univariate analysis 
were selected for inclusion in the multivariate statistical analysis 
(logistic regression) in an attempt to obtain the most parsimoni-
ous model possible.14 The Hosmer-Lemeshow test was used to 
assess the goodness of  fit for the final logistic regression mod-
el. Results for the univariate statistical analysis are presented 
as frequencies and percentages, or medians and IQR, where 
applicable. Results for the multivariate statistical analysis are 
presented as odds ratios (OR) with 95% confidence interval 
(CI).  A p-value of  <0.050 was considered to be a statistically 
significant result.  All statistical analyses were performed using 
the Statistical Package for the Social Sciences (SPSS) version 
25.0 (IBM Corp, USA).   
Study Ethical Approval
This study received ethical approval from the Biomedical 
Research Ethics Committee of  the University of  KwaZulu-
Natal, SA (Protocol: BE046/18).
Results
The process through which the final study sample of  174 pa-
tients was derived is shown in Figure 1.  Perioperative blood loss 
ranged from 10.3mL to 3041.8mL. Mean perioperative blood 
loss was 1103.1 ± 556.2 mL. Median perioperative blood loss 
was 1008.8 mL (IQR: 706.2–1357.0 mL). The 75th percentile 
for perioperative blood loss in the study population was 1357 mL. 
The distribution of  various characteristics in the study sam-
ple is shown in Table 2. The median age of  the study sample 
was 56.0 (IQR: 44.8-65.0). The median height and weight of  
the study sample were 162 cm (IQR: 155.9-169.3 cm) cm and 
78.6 kg (IQR: 67.5-86.1 kg), respectively. A total of  96/174 
patients (55.2%) were female.There were 65/174 patients 
(37.4%) who had an ASA score ≥3. A total of  40/174 patients 
(23.0%) were current smokers. The prevalence of  comorbidity 
ranged from 5.7% (10/174 patients) for cardiovascular disease 
to 48.3% (84/174 patients) for obesity. A total of  6/174 pa-
tients (3.4%) were undergoing surgery for rheumatoid arthritis, 
an established risk factor for perioperative bleeding in primary 
hip arthroplasty patients. Twenty-four patients (13.8% of  the 
study sample) had a fixed flexion deformity of  >30 degrees. 
Mobilization using an assistive device was reported in 75.3% of  
the study population (131/174 patients). Visual analogue score 
(VAS) was ≥7 in 96/174 patients (55.2%). A total of  49/174 pa-
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Table 2. Distribution of characteristics in the study sample and results of 
the univariate statistical analysis*







































Female 96 (55.2) 26 (60.5) 70 (53.4)
Male 78 (44.8) 17 (39.5) 61 (46.6)
ASA score ≥3 0.699
Yes 65 (37.4) 15 (34.9) 50 (38.2)
No 109 (62.6) 28 (65.1) 81 (61.8)
Current smoker 0.641
Yes 40 (23.0) 11 (25.6) 29 (22.1)




Yes 10 (5.7) 3 (7.0) 7 (5.3)
No 164 (94.3) 40 (93.0) 124 (94.7)
COPD 0.040
Yes 21 (12.1) 9 (20.9) 12 (9.2)
No 153 (87.9) 34 (79.1) 119 (90.8)
HIV 0.712
Yes 40 (23.0) 9 (20.9) 31 (23.7)
No 134 (77.0) 34 (79.1) 100 (76.3)
Diabetes 0.764
Yes 16 (9.2) 3 (7.0) 13 (9.9)



































Yes 84 (48.3) 22 (51.2) 62 (47.3)
No 90 (51.7) 21 (48.8) 69 (52.7)
Hypertension
0.432
Yes 80 (46.0) 22 (51.2) 58 (44.3)




Yes 6 (3.4) 2 (4.7) 4 (3.1)
No 168 (96.6) 41 (95.3) 127 (96.9)
tients (28.1%) could not walk a distance of  100m or more.  Ur-
gent/emergent surgery was performed in two patients (1.1% of  
the study population). General anesthesia was used in 90/174 
patient surgeries (51.7%). Surgery was performed via the pos-
terior approach in 117/174 patient surgeries (67.2%).  The du-
ration of  surgery was extended for 32/174 patients (18.4%). 
With regard to perioperative medications which might have in-
fluenced perioperative blood loss, preoperative tranexamic acid 
was administered in 116/174 patients (66.7%) and all patients 
in the study population received postoperative thrombopro-
phylaxis.  No patients had used acetylsalicylic acid within three 
days prior to their surgery.  A total of  24/174 patients (13.8%) 
received a perioperative blood transfusion.
The results of  the univariate statistical analysis are also 
shown in Table 2. The proportion of  patients with chronic ob-
structive pulmonary disease (COPD) was higher in the major 
perioperative blood loss group versus the control group (20.9% 
versus 9.2%, p=0.040). The proportion of  patients who received 
preoperative tranexamic acid was lower in the major periopera-
tive blood loss group versus the control group (44.2% versus 
74.0%, p<0.001). The proportion of  patients who received a 
perioperative blood transfusion was higher in the major peri-
operative blood loss group versus the control group (39.5% ver-
sus 5.3%, p<0.001). There were four characteristics which met 
the criteria (p<0.100) for inclusion in the multivariate statistical 
analysis: COPD, extended duration of  surgery, preoperative 
tranexamic acid, and perioperative blood transfusion.
Figure 1. Derivation of the final study sample
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Table 2. Distribution of characteristics in the study sample and results of 
the univariate statistical analysis* (continued)











FFD >30 degrees 0.407
CNBE 40 (23.0) 13 (30.2) 27 (20.6)
Yes 24 (13.8) 6 (14.0) 18 (13.7)




Yes 131 (75.3) 35 (81.4) 96 (73.3)
No 43 (24.7) 8 (18.6) 35 (26.7)
VAS ≥7 0.347
CNBE 56 (32.2) 13 (30.2) 43 (32.8)
Yes 96 (55.2) 27 (62.8) 69 (52.7)




CNBE 69 (39.7) 13 (30.2) 56 (42.7)
Yes 49 (28.1) 14 (32.6) 35 (26.7)




Yes 2 (1.1) 0 (0.0) 2 (1.5)





Yes 90 (51.7) 25 (58.1) 65 (49.6)




Yes 117 (67.2) 28 (65.1) 89 (67.9)




Yes 32 (18.4) 12 (27.9) 20 (15.3)




Yes 116 (66.7) 19 (44.2) 97 (74.0)
No 58 (33.3) 24 (55.8) 34 (26.0)
Preoperative 
aspirin within 3 
days
0.999
Yes 0 (0.0) 0 (0.0) 0 (0.0)




tory drug within 
3 days
0.752
Yes 56 (32.2) 13 (30.2) 43 (32.8)
No 118 (67.8) 30 (69.8) 88 (67.2)
Table 2. Distribution of characteristics in the study sample and results of 
the univariate statistical analysis* (continued)















Yes 174 (100.0) 43 (100.0) 131 (100.0)




Yes 24 (13.8) 17 (39.5) 7 (5.3)
No 150 (86.2) 26 (60.5) 124 (94.7)
 
*Results expressed as frequencies (%).
p<0.050 was considered a statistically significant result.
ASA: American Society of Anesthesiologists; COPD: Chronic obstructive pulmonary 
disease; IQR: Interquartile range; N/A: Not applicable; CNBE: Could not be established; 
FFD: Fixed flexion deformity; VAS: Visual analogue score.
#Defined as duration of surgery >75th percentile obtained for the study sample.
The results of  the multivariate statistical analysis are shown 
in Table 3. Of  the four characteristics entered into the logistic 
regression analysis, only three were found to be independently 
associated with major perioperative blood loss. Harmful asso-
ciations were observed for COPD (OR: 3.01, 95% CI: 1.01-
8.95; p=0.048) and perioperative blood transfusion (OR: 10.18, 
95% CI: 3.53-29.34; p<0.001).  A protective association was 
observed for preoperative tranexamic acid use (OR: 0.28, 95% 
CI: 0.13-0.63; p=0.002).  The Hosmer-Lemeshow test indicat-
ed that the model fit was appropriate (p>0.05).
 
Table 3. Results of the multivariate statistical analysis*
Characteristic Sub-Category OR (95% CI) p-value












Yes 10.18 (3.53–29.34) <0.001
No Reference -
*Results adjusted for confounders.  Only characteristics with p<0.100 in the univari-
ate statistical analysis were included in the multivariate statistical analysis.
#Defined as duration of surgery >75th percentile obtained for the study sample.
p<0.050 was considered a statistically significant result.
OR: Odds ratio; CI: Confidence interval; COPD: Chronic obstructive pulmonary 
disease. 
Discussion
The levels of  perioperative blood loss observed in our sam-
ple of  SA primary hip arthroplasty patients are in keeping with 
the range of  estimated blood loss observed in the published lit-
erature.3-8  However, around 25% our study population experi-
enced blood loss equivalent to just over 3 units of  packed red 
cells, which is a scarce resource in our setting.9  Besides possible 
implications for healthcare resource utilization (i.e. utilization 
of  blood products), excessive blood loss during the periopera-
tive period might result in anaemia,15 which can predispose pa-
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contributing to haemostasis during the perioperative period.26 
A systematic review and meta-analysis of  randomized con-
trolled trials of  tranexamic acid in hip arthroplasty populations 
reported significant reductions in total blood loss in patients 
who received tranexamic acid versus controls (mean reduc-
tion of  289mL).26  In the same systematic review and meta-
analysis, fewer patients who received tranexamic acid required 
allogenic blood transfusion when compared with controls.  Fur-
thermore, the rate of  perioperative complications was similar 
between tranexamic acid and control groups.26  Therefore, we 
recommend preoperative tranexamic acid be considered for 
the control of  perioperative blood loss in SA primary hip ar-
throplasty patients, unless contraindicated. Contraindications 
for tranexamic acid use include hypersensitivity, a history of  
thrombosis/thromboembolism or if  a patient has an intrinsic 
risk for thrombosis/thromboembolism (for example a patient 
with thrombophilia), a history of  sub-arachnoid hemorrhage, 
or concomitant hormonal oral contraceptive use.27  
Our findings of  an independent association between peri-
operative transfusion and major perioperative blood loss is to 
be expected. Excessive blood loss might prompt surgeons or 
physicians to administer a blood transfusion.2  There is a pro-
portion of  patients however, where excessive blood loss and 
subsequent transfusion can be avoided through careful patient 
management and risk reduction. In our setting this could be 
done through addressing the risk factors for major periopera-
tive blood loss (COPD in our setting) and implementation of  
preventative strategies for perioperative blood loss (preopera-
tive tranexamic acid in our setting), as mentioned earlier. Blood 
products for transfusion are a limited resource in some settings, 
and the use of  these products is usually guided by strict peri-
operative blood management protocols.28,29 Aside from the re-
source implications associated with perioperative blood transfu-
sion, perioperative blood transfusion itself  has also been shown 
to be associated with increased perioperative complications, an 
association which is independent of  anaemia.30 This further 
emphasizes the importance of  addressing major perioperative 
blood loss.  
Our study was not without limitations. A larger sample 
size might have provided more significant data. This study also 
involved patient data from a single SA hospital, and so our 
study findings lack generalizability. There were some patients 
who had missing data for height and/or weight, and we had 
to exclude these patients from the final study sample. In addi-
tion, there were other variables included in our analysis where 
a proportion of  patient data was missing (specifically several 
orthopaedic-related variables). There might have also been 
additional variables relevant to perioperative blood loss in pri-
mary hip arthroplasty patients, but which were not collected as 
part of  the retrospective patient registry and could therefore 
not be investigated in this study. Examples of  these variables 
include socioeconomic status, race, surgeon skill, and other 
medications such as vitamin supplements and herbal medica-
tions which might be associated with increased perioperative 
bleeding.  Socioeconomic status might impact individual food 
security, and hence determine nutritional status.31  Malnutrition 
is known to impair wound healing, and could therefore con-
tribute toward perioperative blood loss.32  There is published 
tients to a variety of  postoperative complications.16,17  A recent 
meta-analysis by Fowler and colleagues found that anaemic 
surgical patients were at an almost 3-fold higher risk of  suffer-
ing postoperative mortality when compared with non-anaemic 
surgical patients (OR: 2.87, 95% CI: 2.10–3.93).16  One of  the 
studies included in the meta-analysis suggested that even mild 
anaemia could be potentially harmful in surgical patients.17 
Furthermore, the study by Musallam and colleagues of  227,425 
noncardiac surgery patients (of  which 30.4% were anaemic) 
found that anaemia was associated with 45-77% higher risk 
of  cardiac complications, a 33-70% higher risk of  respiratory 
complications, a 5-16% higher risk of  neurological complica-
tions, and a 24-88% higher risk of  sepsis when compared with 
a non-anaemic patient group.17  In a sub-analysis of  the Euro-
pean Surgical Outcomes Study (EuSOS), Baron and colleagues 
reported increased length of  hospital stay and postoperative 
admission to intensive care in anaemic versus non-anaemic pa-
tients (p<0.001 for both postoperative outcomes).18  Anaemia is 
also an important determinant of  perioperative blood transfu-
sion, which in itself  is associated with a higher risk of  postop-
erative complications.19,20  Most of  the perioperative complica-
tions associated with anaemia are consequences of  the hypoxia 
associated with the condition.  Our results for blood loss suggest 
that primary hip arthroplasty patients in our setting are poten-
tially at risk of  anemia, and subsequent complications.  
We found that patients with COPD were at a three-fold in-
creased risk of  major perioperative blood loss. This is not the 
first time that COPD has been found to be associated with ex-
cessive perioperative blood loss in an orthopaedic surgery pop-
ulation. Oberweis and colleagues reported a similar harmful 
association between COPD and excessive perioperative blood 
loss in an American orthopaedic surgery population (OR: 2.69 
in the Oberweis study, and OR: 3.01 in our study).21  It is pos-
sible that this finding might actually be related to the pharma-
cologic management of  COPD. Glucocorticoids are commonly 
used to manage COPD. Studies of  non-orthopaedic surgical 
populations report increased perioperative blood loss in patients 
taking glucocorticoids.22,23 Impaired surgical wound healing has 
been postulated as the mechanism which contributes to this in-
creased blood loss in patients who use glucocorticoids.22  This 
appears to be supported by studies of  certain clotting factors, 
which appear to be found in lower concentrations in patients 
who are taking glucocorticoids versus patients who do not take 
these medications.24  A variety of  approaches could be used 
to reduce the risk of  major bleeding in patients with COPD. 
Glucocorticoids might not be necessary in all COPD patients, 
and patients who do not require glucocorticoids should be ad-
vised against the preoperative use of  these medications.25 Non-
pharmacologic approaches for the preoperative optimization 
of  COPD, such as smoking cessation and promoting increased 
physical activity, should also be considered.25 Surgeons and 
anaesthesiologists should also consider deferring surgery in pa-
tients with recent exacerbations of  COPD,25 at least until these 
exacerbations have resolved. 
Preoperative tranexamic acid administration was found to 
be associated with an almost four-fold reduction in the risk of  
major perioperative blood loss in our study.  This is an antifibri-
nolytic agent which inhibits dissolution of  blood clots, thereby 
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evidence to suggest that blood coagulates faster in persons of  
African ethnicity when compared with persons of  Caucasian 
ethnicity.33  It is therefore possible that patients of  African eth-
nicity could have achieved perioperative haemostasis quicker 
and lost less blood than patients from other ethnic groups in 
this study.  With regard to surgeon skill, Glance and colleagues 
found that in surgeries where trainee surgeons performed criti-
cal parts of  the procedure under the supervision of  specialist 
surgeons, there was a significantly higher risk of  intraoperative 
transfusion as a result of  blood loss than if  the procedure was 
performed by a specialist surgeon alone.34 Lastly, medications 
such as vitamin supplements, herbal medicines, and selective 
serotonin reuptake inhibitor antidepressants are known to in-
crease perioperative blood loss.35
Conclusion
The levels of  perioperative blood loss observed in our sam-
ple of  SA primary hip arthroplasty patients are in keeping with 
the range of  estimated blood loss reported in the published lit-
erature.  We found that patients who experienced major peri-
operative blood loss were more likely to have COPD or require 
a perioperative blood transfusion. Preoperative tranexamic acid 
administration was found to be protective against major periop-
erative blood loss. Although our study has important implica-
tions for perioperative protocols in SA orthopaedic surgery set-
tings, we recommend further prospective, multicenter research 
studies be conducted to confirm our findings and address the 
limitations we have outlined.  
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